Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1629 1635
This examiner grants 57% of resolved cases
Michael J. Schmitt is an examiner in Tech Center 1600 and Art Unit 1629. He has overseen 655 resolved cases. The allowance rate for these cases is 56.8 percent. This 56.8 percent rate reflects the frequency of patent grants under his review. Practitioners can use the 655 resolved cases as a baseline for understanding the examination environment in this art unit.
The interview lift is 20.7 percent. This 20.7 percent figure represents the change in the likelihood of allowance following an interview. A positive value of 20.7 percent indicates that interviews are associated with a higher probability of success. This suggests that requesting an interview is a productive strategy for applicants seeking to resolve outstanding issues.
The median days to allowance is 1038. This 1038-day duration is the middle value for the time elapsed from filing to grant. For applicants, this 1038-day median is a key metric for planning the prosecution timeline. By combining the 56.8 percent allowance rate with the 1038-day median, practitioners can develop a data-grounded strategy for Art Unit 1629.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18516552 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER | Non-Final OA | Genentech, Inc. |
| 18289409 | CONJUGATED LINOLEIC ACID SUPPLEMENTATION FOR DISEASE TREATMENT | Final Rejection | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. |
| 18416271 | TREATMENT OF SKIN LESIONS | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18266179 | TREATMENT OF DISORDERS ASSOCIATED WITH LOW BH4 BIOAVAILABILITY | Final Rejection | OXFORD UNIVERSITY INNOVATION LIMITED |
| 17412070 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | Final Rejection | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED |
| 17113571 | METHODS OF TREATING CHEMOTHERAPY OR RADIOTHERAPY INDUCED NEUTROPENIA | Final Rejection | HANMI PHARM. CO., LTD. |
| 18770144 | Methods For Administering Weight Loss Medications | Non-Final OA | Nalpropion Pharmaceuticals LLC |
| 18289331 | GASTRIC RESIDENCE SYSTEMS COMPRISING BUPRENORPHINE AND NALOXONE | Non-Final OA | Nortiva Bio, Inc. |
| 17560549 | USE OF ARIMOCLOMOL IN THE TREATMENT OF NIEMANN PICK DISEASE | Non-Final OA | Zevra Denmark A/S |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy